147 related articles for article (PubMed ID: 21871684)
1. Mother and daughter carrying the same KCNJ11 mutation but with a different response to switching from insulin to sulfonylurea.
Russo C; Salina A; Aloi C; Iafusco D; Lorini R; d'Annunzio G
Diabetes Res Clin Pract; 2011 Nov; 94(2):e50-2. PubMed ID: 21871684
[TBL] [Abstract][Full Text] [Related]
2. Comparison of diabetes phenotype in children and their mothers with permanent neonatal diabetes mellitus carrying the same
Stanik J; Barak L; Dankovcikova A; Valkovicova T; Skopkova M; Gasperikova D
Endocr Regul; 2020 Nov; 54(4):260-265. PubMed ID: 33885251
[No Abstract] [Full Text] [Related]
3. Permanent neonatal diabetes mellitus due to KCNJ11 mutation in a Portuguese family: transition from insulin to oral sulfonylureas.
Dupont J; Pereira C; Medeira A; Duarte R; Ellard S; Sampaio L
J Pediatr Endocrinol Metab; 2012; 25(3-4):367-70. PubMed ID: 22768671
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
Bowman P; Sulen Å; Barbetti F; Beltrand J; Svalastoga P; Codner E; Tessmann EH; Juliusson PB; Skrivarhaug T; Pearson ER; Flanagan SE; Babiker T; Thomas NJ; Shepherd MH; Ellard S; Klimes I; Szopa M; Polak M; Iafusco D; Hattersley AT; Njølstad PR;
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):637-646. PubMed ID: 29880308
[TBL] [Abstract][Full Text] [Related]
5. Detection of KCNJ11 gene mutations in a family with neonatal diabetes mellitus: implications for therapeutic management of family members with long-standing disease.
Abbasi F; Saba S; Ebrahim-Habibi A; Sayahpour FA; Amiri P; Larijani B; Amoli MM
Mol Diagn Ther; 2012 Apr; 16(2):109-14. PubMed ID: 22471336
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers.
Stanik J; Gasperikova D; Paskova M; Barak L; Javorkova J; Jancova E; Ciljakova M; Hlava P; Michalek J; Flanagan SE; Pearson E; Hattersley AT; Ellard S; Klimes I
J Clin Endocrinol Metab; 2007 Apr; 92(4):1276-82. PubMed ID: 17213273
[TBL] [Abstract][Full Text] [Related]
7. Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.
Lau E; Correia C; Freitas P; Nogueira C; Costa M; Saavedra A; Costa C; Carvalho D; Fontoura M
Arch Endocrinol Metab; 2015 Dec; 59(6):559-61. PubMed ID: 26331221
[TBL] [Abstract][Full Text] [Related]
8. Successful transition from insulin to sulfonylurea therapy in a patient with monogenic neonatal diabetes owing to a KCNJ11 F333L [corrected] mutation.
Philla KQ; Bauer AJ; Vogt KS; Greeley SA
Diabetes Care; 2013 Dec; 36(12):e201. PubMed ID: 24265373
[No Abstract] [Full Text] [Related]
9. Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene.
Tonini G; Bizzarri C; Bonfanti R; Vanelli M; Cerutti F; Faleschini E; Meschi F; Prisco F; Ciacco E; Cappa M; Torelli C; Cauvin V; Tumini S; Iafusco D; Barbetti F;
Diabetologia; 2006 Sep; 49(9):2210-3. PubMed ID: 16816952
[No Abstract] [Full Text] [Related]
10. Sulfonylurea vs insulin therapy in individuals with sulfonylurea-sensitive permanent neonatal diabetes mellitus, attributable to a KCNJ11 mutation, and poor glycaemic control.
Stanik J; Dankovcikova A; Barak L; Skopkova M; Palko M; Divinec J; Klimes I; Gasperikova D
Diabet Med; 2018 Mar; 35(3):386-391. PubMed ID: 29278452
[TBL] [Abstract][Full Text] [Related]
11. Transition from insulin to sulfonylurea in a child with diabetes due to a mutation in KCNJ11 encoding Kir6.2--initial and long-term response to sulfonylurea therapy.
Wagner VM; Kremke B; Hiort O; Flanagan SE; Pearson ER
Eur J Pediatr; 2009 Mar; 168(3):359-61. PubMed ID: 18548275
[TBL] [Abstract][Full Text] [Related]
12. Molecular Genetics, Clinical Characteristics, and Treatment Outcomes of K
Ngoc CTB; Dien TM; De Franco E; Ellard S; Houghton JAL; Lan NN; Thao BP; Khanh NN; Flanagan SE; Craig ME; Dung VC
Front Endocrinol (Lausanne); 2021; 12():727083. PubMed ID: 34566892
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up.
Klupa T; Skupien J; Mirkiewicz-Sieradzka B; Gach A; Noczynska A; Zubkiewicz-Kucharska A; Szalecki M; Kozek E; Nazim J; Mlynarski W; Malecki MT
Diabetes Technol Ther; 2010 May; 12(5):387-91. PubMed ID: 20184447
[TBL] [Abstract][Full Text] [Related]
14. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.
Babiker T; Vedovato N; Patel K; Thomas N; Finn R; Männikkö R; Chakera AJ; Flanagan SE; Shepherd MH; Ellard S; Ashcroft FM; Hattersley AT
Diabetologia; 2016 Jun; 59(6):1162-6. PubMed ID: 27033559
[TBL] [Abstract][Full Text] [Related]
15. Permanent neonatal diabetes mellitus caused by a novel mutation in the KCNJ11 gene.
Doneray H; Houghton J; Tekgunduz KS; Balkir F; Caner I
J Pediatr Endocrinol Metab; 2014 Mar; 27(3-4):367-71. PubMed ID: 24150202
[TBL] [Abstract][Full Text] [Related]
16. Successful sulfonylurea treatment of an insulin-naïve neonate with diabetes mellitus due to a KCNJ11 mutation.
Wambach JA; Marshall BA; Koster JC; White NH; Nichols CG
Pediatr Diabetes; 2010 Jun; 11(4):286-8. PubMed ID: 19656320
[TBL] [Abstract][Full Text] [Related]
17. Patterns of postmeal insulin secretion in individuals with sulfonylurea-treated
Bowman P; McDonald TJ; Knight BA; Flanagan SE; Leveridge M; Spaull SR; Shields BM; Hammersley S; Shepherd MH; Andrews RC; Patel KA; Hattersley AT
BMJ Open Diabetes Res Care; 2019; 7(1):e000721. PubMed ID: 31908791
[TBL] [Abstract][Full Text] [Related]
18. Unsuccessful switch from insulin to sulfonylurea therapy in permanent neonatal diabetes mellitus due to an R201H mutation in the KCNJ11 gene: a case report.
Heo JW; Kim SW; Cho EH
Diabetes Res Clin Pract; 2013 Apr; 100(1):e1-2. PubMed ID: 23434183
[TBL] [Abstract][Full Text] [Related]
19. Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encoding Kir6.2.
Kim MS; Kim SY; Kim GH; Yoo HW; Lee DW; Lee DY
J Korean Med Sci; 2007 Aug; 22(4):616-20. PubMed ID: 17728498
[TBL] [Abstract][Full Text] [Related]
20. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Pearson ER; Flechtner I; Njølstad PR; Malecki MT; Flanagan SE; Larkin B; Ashcroft FM; Klimes I; Codner E; Iotova V; Slingerland AS; Shield J; Robert JJ; Holst JJ; Clark PM; Ellard S; Søvik O; Polak M; Hattersley AT;
N Engl J Med; 2006 Aug; 355(5):467-77. PubMed ID: 16885550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
